Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRON Disc Medicine	$54.13 +0.4%	$48.22	$30.82 ▼ $68.73	$1.87B	0.73	342,646 shs	219,894 shs
MESO Mesoblast	$10.75 +1.9%	$11.31	$5.78 ▼ $22.00	$1.35B	2.41	274,883 shs	78,267 shs
SNDL SNDL	$1.25 +2.5%	$1.33	$1.22 ▼ $2.40	$320.59M	3.45	1.95 million shs	1.03 million shs
VERA Vera Therapeutics	$23.29 -0.1%	$22.59	$18.53 ▼ $51.61	$1.49B	1.13	968,751 shs	1.97 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRON Disc Medicine	+0.39%	+8.07%	+17.98%	+3.38%	+24.69%
MESO Mesoblast	+1.90%	-8.04%	-2.01%	-11.23%	+61.90%
SNDL SNDL	+2.46%	-1.57%	-3.10%	-13.79%	-34.55%
VERA Vera Therapeutics	-0.09%	+11.33%	+22.32%	-12.54%	-30.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRON Disc Medicine	2.2467 of 5 stars	3.5	2.0	2.3	2.5	0.0
MESO Mesoblast	2.3269 of 5 stars	3.5	3.0	2.1	0.8	0.6
SNDL SNDL	3.63 of 5 stars	3.5	5.0	2.3	0.0	1.3
VERA Vera Therapeutics	3.3055 of 5 stars	4.6	1.0	2.2	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRON Disc Medicine	3.09	Buy	$96.70	78.64% Upside
MESO Mesoblast	3.00	Buy	$18.00	67.44% Upside
SNDL SNDL	3.00	Buy	$3.63	190.00% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	179.09% Upside

Current Analyst Ratings Breakdown

Latest SNDL, IRON, VERA, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/3/2025	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $65.00
6/2/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $85.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00
5/7/2025	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$34.00 ➝ $26.00
5/7/2025	VERA Vera Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$107.00 ➝ $100.00
5/5/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
MESO Mesoblast	$5.90M	232.82	N/A	N/A	$4.21 per share	2.55
SNDL SNDL	$671.81M	0.49	N/A	N/A	$3.15 per share	0.40
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.29	N/A	N/A	N/A	-11.48%	-9.02%	-7.60%	7/30/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)

Latest SNDL, IRON, VERA, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRON Disc Medicine	0.04	37.65	37.65
MESO Mesoblast	0.22	0.96	0.63
SNDL SNDL	0.10	4.62	3.12
VERA Vera Therapeutics	0.10	27.68	27.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRON Disc Medicine	83.70%
MESO Mesoblast	1.43%
SNDL SNDL	N/A
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
IRON Disc Medicine	4.24%
MESO Mesoblast	18.80%
SNDL SNDL	N/A
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

SNDL, IRON, VERA, and MESO Headlines

Recent News About These Companies

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying Activity

June 26 at 10:11 AM | marketbeat.com

Insider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of Stock

June 26 at 6:52 AM | insidertrades.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 Shares

June 25 at 8:25 PM | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 Shares

June 25 at 8:25 PM | marketbeat.com

Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight

June 24 at 6:45 PM | theglobeandmail.com

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

June 24 at 6:45 PM | finance.yahoo.com

Analysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) PT at $65.00

June 23, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by Brokerages

June 20, 2025 | marketbeat.com

J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

June 19, 2025 | theglobeandmail.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Update

June 18, 2025 | marketbeat.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)

...

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Comments on VERA FY2026 Earnings

June 11, 2025 | marketbeat.com

Q2 EPS Estimates for Vera Therapeutics Increased by Wedbush

June 11, 2025 | marketbeat.com

Vera Therapeutics Inc.

June 10, 2025 | barrons.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2025 | globenewswire.com

Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What Happened

June 9, 2025 | marketbeat.com

Otsuka, Vera stake their claims to IgAN treatment

June 9, 2025 | pharmaphorum.comP

Otsuka's kidney disease therapy trial results heat up battle with rival Vera

June 6, 2025 | msn.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?

June 6, 2025 | marketbeat.com

Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

June 6, 2025 | marketbeat.com

Wedbush Increases Earnings Estimates for Vera Therapeutics

June 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
5 Small Cap Stocks With Explosive Upside Potential
By Ryan Hasson | June 23, 2025
View 5 Small Cap Stocks With Explosive Upside Potential
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

SNDL, IRON, VERA, and MESO Company Descriptions

Disc Medicine NASDAQ:IRON

$54.13 +0.21 (+0.39%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$54.28 +0.15 (+0.29%)

As of 06/26/2025 06:18 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Mesoblast NASDAQ:MESO

$10.75 +0.20 (+1.90%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$10.76 +0.01 (+0.09%)

As of 06/26/2025 04:04 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

SNDL NASDAQ:SNDL

$1.25 +0.03 (+2.46%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.25 0.00 (-0.40%)

As of 04:44 AM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Vera Therapeutics NASDAQ:VERA

$23.29 -0.02 (-0.09%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$23.28 -0.02 (-0.06%)

As of 04:44 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time